作者: R.P. Hasserjian
DOI: 10.1016/B978-0-12-386456-7.04103-4
关键词:
摘要: Acute myeloid leukemia (AML) is an aggressive neoplasm characterized by arrest of hematopoietic maturation, resulting in increased myeloblasts the blood and bone marrow. Current treatment strategies for AML are based on both patient-related parameters such as age performance status intrinsic disease biology. The latter heavily influenced genetic abnormalities present stem cells. Traditionally, cytogenetic were paramount determining prognosis; however, about 40% AMLs have a normal karyotype. In recent years, rapidly increasing information becoming available regarding gene mutations normal-karyotype their influence prognosis. Key exhibit complex interactions with one another also epigenetic alterations driving Future therapies will increasingly rely signatures individual leukemias future adjust therapy to predicted aggressiveness employ targeted against particular deregulated pathways.